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ABSTRACT
Background: The authors investigated the effect of a single
preoperative bolus of erythropoietin on perioperative trans-
fusion requirement and erythropoiesis in patients with pre-
operative anemia undergoing valvular heart surgery.
Methods: In this prospective, single-site, single-blinded,
randomized, and parallel-arm controlled trial, 74 patients
with preoperative anemia were randomly allocated to either
the erythropoietin or the control group. The erythropoietin
group received 500 IU/kg erythropoietin and 200 mg iron
sucrose intravenously 1 day before the surgery. The control
group received an equivalent volume of normal saline. The
primary endpoint was transfusion requirement assessed dur-
ing the surgery and for 4 days postoperatively. Reticulocyte
count and iron profiles were measured serially and compared
preoperatively and on postoperative days 1, 2, 4, and 7.
Results: Transfusion occurred in 32 patients (86%) of the
control group versus 22 patients (59%) of the erythropoietin
group (P  0.009). The mean number of units of packed
erythrocytes transfused per patient during the surgery and for
4 postoperative days (mean  SD) was also significantly
decreased in the erythropoietin group compared with the
control group (3.3  2.2 vs.. 1.0  1.1 units/patient, P 
0.001). The reticulocyte count was significantly greater in
the erythropoietin group at postoperative days 4 (P 0.001)
and 7 (P  0.001).
Conclusions: A single intravenous administration of eryth-
ropoietin and an iron supplement 1 day before surgery sig-
nificantly reduced the perioperative transfusion requirement
in anemic patients undergoing valvular heart surgery, impli-
cating its potential role as a blood conservation strategy.
C ARDIAC surgery using cardiopulmonary bypass(CPB) poses a major hemostatic challenge frequently
requiring transfusion of allogeneic blood products.1 How-
ever, blood transfusion carries risks far beyond transmission
of infectious diseases and has been clearly demonstrated to be
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What We Already Know about This Topic
• Blood transfusion carries many risks beyond transmission of
infectious diseases, including major morbidity and mortality
• Avoiding transfusion by increasing endogenous erythrocyte
production could also avoid these complications
What This Article Tells Us That Is New
• A single intravenous administration of erythropoietin and an
iron supplement 1 day before surgery significantly reduced the
perioperative transfusion requirement in anemic patients un-
dergoing valvular heart surgery, implicating its potential role as
a blood conservation strategy
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associated with adverse outcomes related to postoperative
acute kidney injury, neurologic complication, atrial fibrilla-
tion, acute lung injury, and increasedmortality.2–6 Thus, the
importance of blood conservation strategies to minimize
transfusion is being increasingly emphasized.7
Recombinant human erythropoietin (rHuEPO) was de-
veloped to treat the anemia associated with reduced erythro-
poiesis caused by chronic renal disease and some hematologic
diseases.8,9 Several studies have demonstrated the efficacy of
preoperative rHuEPO administration for cardiac surgery to
restore erythrocyte transfusion in patients having autologous
blood donations.10,11 rHuEPO has also been demonstrated
to be safe and effective to improve preoperative anemia, and
it can be used in conjunction with iron therapy in patients
with hemoglobin concentrations less than 13 g/dl.12,13How-
ever, a typical preoperative regimen of rHuEPO is costly and
requires at least 4 days of hospitalization before the surgery,
limiting the more widespread use of this strategy.1 Outpa-
tient-based repeated injections of rHuEPO via the subcuta-
neous route may be feasible12; however, it may be related to
the increased occurrence of therapy-related complications
such as hypertension and thromboembolism.14 In addition,
the absorption of subcutaneously administered rHuEPO
may not be consistent and reliable compared with the intra-
venous route due to decreased microcirculation in patients
with cardiac disease.15
During the postoperative period, the decrease in hemo-
globin concentration in the absence of further blood loss is
accompanied by a state of relative hypoferremia with a
blunted increase in the concentration of erythropoietin and
reticulocytes persisting for more than 1 week and mediated
by the ensuing systemic inflammatory response.16–19 There-
fore, in the context of optimizing inpatient procedures,
switching the target of rHuEPO therapy from increasing the
preoperative hemoglobin concentration to potentially miti-
gating the inflammatory response-induced blunted erythro-
poiesis would greatly reduce the related cost without influ-
encing the duration of preoperative hospitalization.
Considering that the inflammatory response initiates with
the induction of anesthesia, a single preemptive intravenous
bolus of rHuEPO with iron supplementation could result in
enhanced postoperative erythropoiesis and the reduced re-
quirement for transfusion. This single dose approach was
demonstrated to be effective in terms of hemoglobin concen-
tration and transfusion requirement immediately from post-
operative day (POD) 1 in orthopedic surgical patients,20 yet
no comprehensive data exist to support this hypothesis.
We designed this prospective single-site, single-blinded,
randomized, and parallel-arm controlled trial to investigate
the effect of a single preoperative intravenous bolus of
rHuEPO on perioperative transfusion requirement in pa-
tients with preoperative anemia undergoing valvular heart
surgery (VHS). The primary endpoint was to compare peri-
operative transfusion requirement in terms of overall inci-
dence and mean number of units of packed erythrocytes
transfused per patient during the surgery and for 4 days after
surgery. Secondary endpoints were comparisons of daily
transfusion requirement during the postoperative period un-
til the fourth POD, serial changes of hemoglobin concentra-
tion, reticulocyte count, iron profiles, and occurrence of
postoperative complications.
Materials and Methods
Patients
This trial was conducted at Yonsei UniversityHealth System,
Seoul, Korea between April 2009 and April 2010. The study
protocol was approved by the Institutional Review Board of
Severance Hospital, Yonsei University Health System and
was performed in full compliance with the Declaration of
Helsinki. Participants were recruited from the Anesthesiol-
ogy Preoperative Evaluation Clinic and gave written in-
formed consent. Seventy-four patients scheduled for VHS
and who had preoperative anemia were enrolled. Patients
were randomly allocated to either the rHuEPOor the control
group in a 1:1 ratio bymeans of computer-generated random
numbers. A ward physician not involved in the current trial
performed randomization and assignment. We defined ane-
mia as a hemoglobin concentration less than 12 g/dl in
women and less than 13 g/dl in men according to World
Health Organization criteria.21 Patients with preexisting un-
controlled hypertension (diastolic blood pressure more than
100 mmHg), platelet count more than 450,000/mm3, his-
tory of thromboembolism, seizure, malignant disease, liver
dysfunction, confirmed renal impairment (serum creatinine
[Cr] 2 mg/dl), aplastic or iron deficiency anemia and/or
acute hyperparathyroidism, and hypersensitivity to iron
therapy were excluded.
Treatment
Patients in the rHuEPO group received 500 IU/kg rHuEPO
(Epocain prefilled, CJ Pharma Co., Ltd., Seoul, Korea) via
intravenous bolus administration at 16–24 h before surgery.
At the same time, 200 mg iron sucrose supplement (Veno-
ferrum, BYK Gulden, Inc, Singen, Germany) mixed with
100ml normal saline was administered intravenously for 1 h.
The patients in the control group received an equivalent
volume of normal saline for the same duration without iron
supplementation. Medications were prepared and adminis-
tered by a ward physician recognizing the patient’s group but
not involved in the current study, whereas the surgeon and
anesthesiologist involved in the study and patient manage-
ment were blinded to the patients’ groups until the end of the
study.
Clinical Evaluations
Primary endpoints were comparisons of perioperative trans-
fusion requirement in terms of overall incidence and mean
number of units of packed erythrocytes transfused per pa-
tient during the operation and for 4 PODs. Secondary end-
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points were comparisons of daily packed erythrocytes re-
quirement during the postoperative period until the fourth
POD, serial changes of hemoglobin concentration, reticulo-
cyte count, iron profiles, and occurrence of postoperative
complications. At our institution the mediastinal tube is usu-
ally removed 4 days after surgery. We followed up on the
amount of allogeneic packed erythrocytes transfusions and
bleeding up to POD 4. Hemoglobin concentration less than
7 mg/dl during CPB, and less than 8 mg/dl after CPB and
postoperatively, were used as transfusion thresholds. Intra-
operatively, we measured the hemoglobin concentration
postinduction and every 30 min during CPB, then at 10 min
post-CPB and poststernal closure, and postoperatively at the
time of and 8 h after arrival at the intensive care unit. After
the day of surgery, we measured the hemoglobin concentra-
tion once in themorning if there was no excessive bleeding or
symptoms of anemia. The patients who had hemoglobin
concentrations higher than 8 mg/dl postoperatively, yet re-
quired transfusion due to symptoms of acute anemia such as
shortness of breath, change in respiratory rate and pulse rate,
mental function deterioration, and myocardial ischemia
were excluded from the study.22
Preoperative variables included demographic data, type of
surgery, comorbid conditions (including presence of diabetes
mellitus, hypertension, chronic renal failure, cerebrovascular
accidents, and/or congestive heart failure), and medications.
We also measured the risk of early mortality in patients un-
dergoing cardiac surgery by the logistic EuroSCORE.23 In-
traoperative variables included anesthesia time, duration of
aortic cross clamp and CPB, fluid balance including blood,
fluid, and cell saver input, and urine output. Postoperative
variables included the amount of bleeding measured by chest
tube drainage for 4 days after surgery, fluid input, urine
output, and amount of allogeneic blood transfusion. Hemo-
globin concentrations were measured preoperatively, at post-
anesthetic induction, and POD 0 (day of the surgery after
arrival in the intensive care unit), 1, 2, 3, 4, and 7. Reticulocyte
count and iron profiles including serum iron concentrations,
total iron binding capacity, and ferritin concentrations, and
transferrin saturationweremeasured preoperatively and at post-
anesthetic induction and POD 1, 2, and 7, and the changes in
reticulocyte count from the baseline values ( reticulocyte
count)were calculated. Postoperative variables also included the
incidence of perioperative multiple allogeneic transfusion, in-
cidence of acute kidney injury (AKI) within 48 h after sur-
gery, atrial fibrillation for 7 days after surgery, duration of
ventilator care, intensive care unit stay and hospital stay, and
in-hospital mortality. Multiple allogeneic transfusion was
defined as transfusion of more than 1 unit of packed eryth-
rocytes during the operation and for 4 PODs. AKI was de-
fined as elevation of serum Cr of 0.3 mg/dl or 50–200%
from baseline using modified Risk, Injury, Failure, Loss, and
End-stage Kidney Disease classification.24,25 Surgical mor-
tality was defined as all deaths that occurred during the hos-
pital stay or after hospital discharge but within 30 days post-
operatively. Possible complications associated with rHuEPO
therapy such as hypertension, thromboembolism, headache,
tachycardia, nausea, vomiting, hypercalcemia, and diarrhea
were also assessed from the beginning of the administration
of rHuEPO until hospital discharge. Although our study was
not designed to validate the difference in outcome variables
such as AKI, atrial fibrillation, duration of ventilator care,
intensive care unit, and hospital stay, and surgical mortality,
it could be informative to provide postoperative outcome
variables to demonstrate that erythropoietin therapy did not
appear to be associated with adverse outcome.
Perioperative Management
All patients were premedicated with 0.05 mg/kg intramus-
cular morphine 1 h before arriving in the operating room.
Five electrocardiogram leads were attached, and leads II and
V5 were continuously monitored. A 20-G radial artery cath-
eter was inserted under local anesthesia. For continuous car-
diac output monitoring, a thermodilutional pulmonary ar-
tery catheter (Swan-Ganz, CCOmbo, Baxter Healthcare
Co., Irvine, CA) was inserted via the right internal jugular
vein under local anesthesia. After that, anesthesia was in-
duced with 0.05 mg/kg midazolam, 1.5 g/kg sufentanil,
and 50 mg rocuronium, and maintained with continuous
infusion of sufentanil at 0.5 g  kg1  h1, vecuronium at
8–10 mg/h, and a low dose of sevoflurane in oxygen (40–
60%) with air during the surgery. A transesophageal echo-
cardiographic probe was inserted to monitor global myocar-
dial function and assess the replaced valves. Arterial oxygen
saturation, end-expiratory sevoflurane concentration, and
nasopharyngeal and rectal temperatures weremonitored dur-
ing the study. Mechanical ventilation was controlled to
maintain normocapnia. The depth of anesthesia was moni-
tored with a Bispectral Index score monitor (A-200 Bispec-
tral Index score monitor, Aspect Medical System Inc.,
Newton, MA) and maintained at 40–60. Any mean arterial
pressure less than 60 mmHg was treated with norepineph-
rine. CPB was instituted with a membrane oxygenator
primed with 1.6 l priming solution, which consisted of 100
ml 20% human albumin, 20% mannitol (5 ml/kg),
NaHCO3 (20 mEq), heparin (2,000 IU), sufentanil 1.5 g/
kg, midazolam 0.05 mg/kg, and acetated Ringer’s solution
(Plasma Solution A Inj., CJ Pharma, Seoul, Korea). Body
temperature was cooled to 32–33°C. A nonpulsatile pump
flow rate was maintained at 2.0–2.5 l min1 m2. During
the period before and after CPB, crystalloid solution was
infused at a fixed rate of 6–8ml  kg1  h1, whereas colloid
solution (Voluven, Fresenius Kabi, Bad Homburg, Ger-
many) was infused to compensate for the amount of blood
loss at a maximal dose of 20 mg  kg1  day1. All patients
received a loading dose of 1 g tranexamic acid followed by an
infusion of 200 mg/h during the surgery, and another load-
ing dose of 1g with the onset of CPB. Blood salvaged by the
cell salvage device was reinfused into the patient before the
end of surgery. This trial was overseen by an independent
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data safety monitoring board. The independent committee
had reviewed our data when 15%, 33%, and 66% of the
anticipated number of patients were accumulated for ensur-
ing safe and ethical treatment of research participants, data
quality, and credibility of study findings.
Statistical Analysis
Continuous variables were shown as means SD and dichot-
omous variables were shown as numbers (percentages). Be-
tween-group comparisons of continuous variables were per-
formed by independent Student t test. Dichotomous variables
were compared using chi-square or Fisher exact tests, as appro-
priate. Hemoglobin, reticulocyte count, and iron profiles were
analyzed using a linear mixed model with patient indicator as a
random effect, group, time, and group-by-time as fixed effects.
All statistical tests were two-tailed. P values less than 0.05 were
considered statistically significant. This study was designed to
validate the superiority of rHuEPO treatment. In a previous
study using aprotinin,26 the transfusion rate in the control
group was 44%. A power estimation analysis of that study sug-
gested that 32 patients per group would be required to obtain a
power of 80%, considering a type I error of 0.05, and expecting
a reduction from 44% to 13% in the incidence of allogeneic
erythrocyte transfusion. All statistical analyses were performed
using SPSS software version 15.0 (SPSS Inc., Chicago, IL).
Results
VHS could be performed as planned in all patients, and
complete data sets from the 74 patients were analyzed with-
out any missing data.
Patients’ characteristics and performed surgeries were similar
between the groups (table 1). There were no patients with he-
moglobin concentrations higher than 8 mg/dl and symptoms
such as shortness of breath, change in respiratory rate and pulse,
mental function deterioration, and myocardial ischemia, al-
though that would have required transfusion.
Surgical characteristics including anesthesia time, dura-
tion of aortic cross clamp and CPB, and fluid balance includ-
ing the amount of ultrafiltration were similar between the
groups (table 2).
During the perioperative period combining the values
during surgery and 4PODs, the mean number of units of
packed erythrocytes transfused per patient (3.3  2.2 vs.
1.0 1.1 units/patient, P 0.001), mean number of units
of packed erythrocytes transfused per transfused patient
(3.7 2.1 vs. 1.6 0.9 units/patient who received erythro-
cyte transfusion, P 0.004), and number of patients trans-
fused with allogeneic erythrocyte (32 vs. 22, P 0.009) were
significantly less in the rHuEPO group. In detail, the num-
ber of patients transfused with erythrocyte during surgery
was similar between the groups, whereas themean number of
units of packed erythrocytes transfused per patient during
surgery was significantly greater in the control group. During
the postoperative period, the amount of blood loss was sim-
ilar between the groups. In contrast, the mean number of
units of packed erythrocytes transfused per patient and the
number of patients transfused with allogeneic erythrocyte at
POD0, 1–2, and 3–4, and during 4 PODswere significantly
less in the rHuEPO group (table 3). Total amounts of fluid
input and urine output during 4 PODs were similar between
the groups.
The lowest postoperative hemoglobin concentrations
were significantly higher in the rHuEPO group at PODs 2,
3, and 4. Reticulocyte count at PODs 4 and 7, and  reticu-
Table 1. Patient Demographics and Preoperative
Clinical Data
Control
(n  37)
rHuEPO
(n  37)
P
Value
Age (yr) 59  12 56  12 0.208
Female sex 23 (62.2) 24 (64.9) 0.809
BMI (kg/m2) 23  4 23  3 0.994
Operation
AVR 16 (41.7) 12 (31.4) 0.338
MVR 14 (37.8) 14 (37.8) 0.999
DVR 5 (13.5) 4 (10.8) 0.722
Valve  CABG 0 (0) 2 (5.4) 0.493
Bental 2 (5.4) 5 (13.5) 0.430
Redo 3 (8.1) 1 (2.7) 0.615
DM 3 (8.1) 7 (18.9) 0.308
Hypertension 14 (37.8) 9 (24.3) 0.209
CVA 2 (5.4) 1 (2.7) 0.999
CHF 2 (5.4) 1 (2.7) 0.999
Medications
blockers 15 (41.7) 8 (21.6) 0.065
CCB 6 (16.7) 5 (13.5) 0.707
ACEi 10 (27.8) 8 (21.6) 0.542
ARB 9 (25) 10 (27) 0.844
Diuretics 17 (50) 17 (50) 0.913
EuroSCORE 3.6  2.2 3.9  2.3 0.538
Values are mean  SD or number of patients (%).
ACEi  angiotensin-converting enzyme inhibitor; ARB  angio-
tensin receptor blocker; AVR  aortic valve replacement;
BMI  body mass index; CCB  calcium channel blockers;
CHF  congestive heart failure; CVA  cerebrovascular acci-
dent; DM  diabetes mellitus; DVR  double valve replacement;
MVR mitral valve replacement; rHuEPO  recombinant human
erythropoietin; Valve  CABG  valvular replacement with cor-
onary artery bypass grafting.
Table 2. Intraoperative Parameters
Control
(n  37)
rHuEPO
(n  37)
P
Value
Anesthesia time (min) 293  76 289  66 0.800
ACC time (min) 85  26 82  33 0.770
CPB time (min) 115  35 113  40 0.940
Fluid balance
Crystalloid (ml) 1,731  917 1,763  846 0.850
Colloid (ml) 685  454 630  306 0.564
Urine output (ml) 1,018  689 1,165  964 0.451
Values are mean  SD.
ACC time  duration of aortic cross clamp; CPB time  duration
of cardiopulmonary bypass; rHuEPO  reombinant human
erythropoietin.
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locyte count at PODs 2, 4, and 7 were significantly higher in
the rHuEPO group (table 4). After additional adjustment for
-blocker use in our between-group comparisons of reticu-
locyte response over time using linear mixed model assess-
ment, the results were not different from presented analysis.
Serum iron concentrations, total iron binding capacity,
and ferritin and transferrin saturation were similar between
the groups, with the exception of significantly higher serum
iron and transferrin saturation after anesthetic induction in
the rHuEPO group (fig. 1).
During the postoperative period, significantly fewer pa-
tients received multiple transfusions in the rHuEPO group.
The number of patients who developed AKI was also signif-
icantly less in the rHuEPO group. The duration of ventilator
care and intensive care unit stay demonstrated trends toward
being shorter in the rHuEPO group without statistical sig-
nificance. Other variables including the mortality rate were
not different between the groups (table 5).
In both groups, there were no patients who developed
complications associated with rHuEPO therapy such as hy-
pertension, headache, tachycardia, nausea, vomiting, hyper-
calcemia, and diarrhea.
Discussion
In this randomized controlled trial addressing the efficacy of
a single preemptive dose of rHuEPO and iron supplementa-
tion at 1 day before VHS on reducing transfusion requirement
in patients with preoperative anemia, we observed a statistically
significant reduction in the number of patients requiring trans-
Table 3. Perioperative Transfusion Requirement and Postoperative Blood Loss
Group
Intra-
Operative POD 0
POD
1–2
POD
3–4
Postoperative
Total
Perioperative
Total
Amount of blood loss Control 321  287 366  305 79  248 766  558
(ml) rHuEPO 307  276 301  206 19  41 624  380
Amount of erythrocytes Control 1.2  1.1 0.9  1.1 0.8  1.3 0.4  0.9 2.1  1.9 3.3  2.2
(units/patient) rHuEPO 0.7  0.7* 0.2  0.6* 0.1  0.3* 0  0* 0.3  0.8* 1.0  1.1*
Amount of erythrocytes/ Control 1.7  1.0 1.7  1.1 2.6  1.0 2.0  0.9 2.8  1.8 3.7  2.1
transfused patients
(units/transfused patient)
rHuEPO 1.4  0.6 1.6  0.9 2 2.0  1.4 1.6  0.9*
Patients transfused Control 25 (67.7) 20 (54.1) 10 (27) 8 (21.6) 27 (73) 32 (86.5)
with erythrocytes
(n)
rHuEPO 20 (54.1) 5 (13.5)* 1 (2.7)* 0 (0)* 5 (13.5)* 22 (59.5)*
Mean hemoglobin Control 9.0  0.8 8.8  1.0 8.7  0.8
concentrations
(mg/dl)
rHuEPO 9.3  1.0 9.3  0.9* 9.0  0.8
Values are mean  SD or number of patients (%).
* P  0.05 vs. control group.
Amount of erythrocytes  number of units of erythrocytes transfused for the entire study group divided by the total number of subjects
in that study group; Amount of erythrocytes/transfused patients number of units of erythrocytes transfused for the entire study group
divided by the number of transfused patients in that study group; Perioperative  intraoperative plus postoperative; POD 
postoperative day; POD 0  day of the surgery after arrival in the intensive care unit; rHuEPO  recombinant human erythropoietin.
Table 4. Changes of Hematopoietic Factors
Group Preoperative
Post
Induction POD 0 POD 1 POD 2 POD 3 POD 4 POD 7
Hemoglobin (g/dl)
Control 11.6  1.2 11.5  1.4 9  1† 8.8  1.2† 8.4  0.9† 8.2  0.9† 8.3  1.1† 9.4  1.3†
rHuEPO 11.8  0.8 11.6  1.2 9.4  1.3† 9.5  1.0† 9.4  0.8*† 9.3  0.7*† 9.4  0.9*† 9.5  1.0†
Reticulocyte count
(103/l)
Control 73  30 75  27 61  22 64  26 68  28 105  45†
rHuEPO 70  26 80  24 72  24 73  23 92  25*† 164  52*†
 Reticulocyte count
(103/l)
Control 1  14 –14  16 –11  22 0  22 32  44
rHuEPO 10  13 –3  18 0  21* 13  24* 93  52*
Values are mean  SD. Hemoglobin concentrations on POD 0 to POD 7 are the lowest values among evaluations taken each day.
* P  0.05 vs. control group; † P  0.05 vs. baseline value.
POD  postoperative day; POD 0  day of the surgery after arrival in the intensive care unit; rHuEPO  recombinant human
erythropoietin;  Reticulocyte count  change in reticulocyte count from the preoperative values.
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fusion as well as the mean number of units of packed erythro-
cytes transfused per patient during the perioperative period in
the rHuEPO group. The degree of decrease in reticulocyte
counts was less at PODs 2, 4, and 7 in the rHuEPO group
compared with the control group, and enhancement of eryth-
ropoiesis was observed fromPOD4with statistical significance.
Allogeneic blood transfusion is a recognized risk factor for
morbidity and mortality after cardiac surgery.4,5 Despite ef-
forts to reduce allogeneic blood transfusion, it remains com-
mon in cardiac surgery.5 rHuEPO treatment with or without
preoperative autologous blood donation is known to reduce
allogeneic blood transfusion.1,10–13 However, the require-
ment for repeated rHuEPO injections for an interval of sev-
eral days was considered time-consuming and was associated
with the potential risk of thromboembolic complications.
In addition to surgical bleeding and coagulopathy, postop-
erative anemia is aggravatedby systemic inflammatory response-
induced erythropoiesis inhibition.16–19 Postoperative anemia is
characterized as a relative erythropoietin- and iron-deficient
state and a resultant serial reduction of hemoglobin concentra-
tions for several days.17 The degree of postoperative anemia due
to inflammation is related to the extent of surgery.18 Cardiac
surgery using CPB would thus be presumed to be associated
withmore blunted erythropoiesis and interferenceof ironmetab-
olism and to augment postoperative anemiamore thannoncardiac
surgery would.27 Several studies have aimed to determine whether
the speed of recovery frompostoperative anemia can be accelerated
with postoperative rHuEPO treatment. During the postpartum
period in patients with anemia, a single postoperative injection of
rHuEPO was reported to activate blunted postoperative erythro-
poiesis and to effectively correct anemia.28However, postoperative
use of rHuEPO failed to increase hemoglobin concentrations de-
spite increased reticulocyte count inmost studies.17,29
Recently, in an attempt to develop amore practical regimen,
five rHuEPO injections for 2 days before off-pump coronary
artery bypass surgery was reported to diminish postoperative
allogeneic blood transfusions.13 Another study reported a
higher postoperative hemoglobin concentration after coronary
artery bypass surgery by administering three doses of rHuEPO
starting on the day before surgery. However, the primary end-
point of that studywas to elucidate the neuroprotective effect of
rHuEPO, and the sample size was too small to draw any con-
clusion in terms of blood conservation.30 Yet, the role of preemp-
tive single rHuEPObolus therapy as a blood conservation strategy
in preoperatively anemic patients undergoing cardiac surgery with
CPB has not been comprehensively evaluated to date.
Because our primary objective was to validate the efficacy
of a single dose of rHuEPO before the surgery without re-
quiring additional hospital stays, we used a rather high single
dosage,whichwas almost thehighestdoseof intravenously injected
rHuEPO (500 IU/kg) that has been used in clinical studies.10,31
Becausewewanted to test the feasibility andefficacyof this regimen
Fig. 1. Changes of serum iron (A), TIBC (B), ferritin (C) concentra-
tions, and transferrin saturation (D) over time in the control group
and rHuEPO group. Values are mean SD. * P 0.05 compared
with the control group. † P  0.05 compared with the baseline.
POD  postoperative days; postind  postanesthetic induction;
preop preoperative; rHuEPO recombinant human erythropoi-
etin; TIBC  total iron binding capacity.
Table 5. Postoperative Outcome
Control (n  37) rHuEPO (n  37) P Value
Multiple transfusion, yes 20 (54.1) 5 (13.5) 0.0001
Postoperative AKI, yes 19/35 (54.3) 9/37 (24.3) 0.017
Postoperative AF, yes 9/30 (30) 6/28 (21.4) 0.456
Duration of ventilator care (h) 18.9  8.9 16  4.6 0.085
Duration of ICU stay (h) 68.1  49.1 51.7  21.5 0.068
Duration of hospital stay (days) 13.5  8.0 11.3  4.1 0.133
Death 1 (2.7) 0
Values are mean  SD.
AF  atrial fibrillation; AKI  acute kidney injury; Death  all deaths that occurred during the hospital stay or after hospital discharge
but within 30 days postoperatively; ICU  intensive care unit; Multiple transfusion  transfusion of  1 unit of packed erythrocytes
during the operation and for 4 postoperative days; rHuEPO  recombinant human erythropoietin.
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on reducing transfusion requirement within the timeframe of rou-
tine hospital admission policies for elective VHS at our institution,
we administered rHuEPO at 1 day before the surgery.
Our data revealed that the transfusion requirement of
allogeneic erythrocyte in the rHuEPO group during the peri-
operative as well as the postoperative period was statistically
significantly reduced. Impressively, only a single patient re-
quired transfusion after the day of surgery in the rHuEPO
group while several patients were repeatedly transfused dur-
ing the postoperative period in the control group. rHuEPO
treatment was accompanied by less of a reduction in reticu-
locyte count and statistically significant enhancement of
erythropoiesis compared with the control group.
Regarding the treatment of temporarily depressed eryth-
ropoiesis, existing evidence supports the rapid beneficial he-
matologic effect of a single high dose of rHuEPO during the
perioperative period. Reticulocyte counts have been demon-
strated to readily increase after rHuEPO injection in a dose-
dependentmannerwhile a peak response occurred at 4 to 5 days
after a single injection.32 In that study, rHuEPO has been pro-
posed to act on the mature erythroblasts to give rise to an early
24-h reticulocyte response. In our study, the increase in absolute
reticulocyte counts compared with baseline values could be ob-
served only at PODs 4 and 7 in the rHuEPO group, in accor-
dance with most previous studies.1,32 However, the  reticulo-
cyte counts were constantly higher in the rHuEPO group,
bearing statistical significance as early as POD 2, whereas no sta-
tistically significant increase in reticulocyte countswasobservedun-
til POD7 in the control group. These findings support the role of
single preemptive rHuEPO treatment in reduced transfusion re-
quirement, because other known risk factors of transfusion were
similar between the groups. Still, additional mechanisms account-
ing for the acute effect of rHuEPO on postoperative transfusion
requirement should be investigated.
Although there was no statistical significance, more patients
received-blocker therapy in the control group, which could be
a confounding factor because -adrenergic agonists can stimu-
late erythropoietin secretion.33 Therefore, we also adjusted for
-blocker use inourbetween-group comparisons of reticulocyte
response over time usingmixed linearmodel assessment; similar
results were observed as in our presented analyses.
In the control group, cardiac surgery led to changes in iron
metabolism such as a decrease in serum iron and transferrin satura-
tion and an increase in serum ferritin concentration, in agree-
mentwithprevious studies.18Because the amount of stored iron
needed to replace 1 g/dl hemoglobin is 150 mg,17 and inflam-
mation decreases intestinal iron absorption,34 we administered
200 mg iron intravenously. In the rHuEPO group, despite in-
travenous iron supplementation 1 day before the surgery, the
serum iron concentration and transferrin saturation increased
only during the postinduction period. This may be associated
with the fact that supplied iron is rapidly cleared during in-
creased erythropoiesiswith an erythrocyte uptakeof 80–90%.35
Several studies have suggested that erythropoietin has pro-
tective action against ischemia-reperfusion injury in the kidney,
heart, and brain.36 A recent clinical study reported that admin-
istration of 300 IU/kg rHuEPO to patients undergoing coro-
nary artery bypass surgery reduced the incidence of AKI and
improved postoperative renal function, although information for
allogeneic blood transfusionwas unclear.37 Interestingly, the num-
ber of patients who developed AKIwas less in the rHuEPOgroup
in our study, with statistical significance. However, because trans-
fusion is an independent risk factor for AKI after cardiac surgery38
and the transfusion rate was lower in the rHuEPO group, it is
unclear whether preserved postoperative renal function is due to a
renoprotective effect of rHuEPO. We also noted distinct trends
toward shorter duration of ICU stay and hospitalization in the
rHuEPOgroup.Our studywas not designed to validate the bene-
ficial effects of rHuEPO therapy on postoperative outcome, and
this subject merits further studies with a proper sample size.
The possible complications of rHuEPO therapy include hy-
pertension, headache, tachycardia, nausea, vomiting, hypercal-
cemia, diarrhea, and thromboembolic complication. However,
these complications usually occur in patients who receive
chronic, repeated erythropoietin therapy.1,12 More impor-
tantly, chronic use in cancer patients is associatedwith increased
thrombotic risk, but short-term use for acute indications cur-
rently appears to be safe, even in critically ill patients.31,39 In
addition, thromboembolic complication is known to be pro-
portional to the blood hemoglobin concentration,40 while we
enrolled preoperatively anemic patients for whom preoperative
use of rHuEPOwas reported to be most beneficial.15 Although
complete correction of anemia might accentuate vasoconstric-
tion and increase blood pressure and the risk of thrombosis,41 our
studywas not targeted to correct preoperative anemia, and none of
the patients had hemoglobin concentrations above 12 g/dl
throughout the study period. Accordingly, none of the patients
experienced any complications.Our study demonstrated the safety
of a large preemptive single intravenous dose of rHuEPO.
The limitations of this study are as follows. The theoretic
background selecting the timing of rHuEPO administration
in this study was based on the assumption that a preemptive
single dose of rHuEPO may mitigate the inflammatory re-
sponse-induced blunted erythropoiesis. However, this hy-
pothesis remains speculative because we did not evaluate the
representative inflammatory markers. Although we excluded
patients with iron deficiency anemia, a relative iron-deficient
state occurs during the postoperative period.17 Therefore,
iron supplementation alone may have influenced the result,
which was not given in the control group.
In conclusion, a single 500 IU/kg intravenous rHuEPO
injection and concomitant iron supplementation 1 day be-
fore surgery resulted in statistically significant reduction of
perioperative transfusion requirement in anemic patients un-
dergoing VHS. Given the lack of complications of our treat-
ment protocol and its compatibility with current inpatient
optimization procedures, it should be considered as a prom-
ising blood conservation strategy in patients with preopera-
tive anemia who are undergoing VHS.
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ANESTHESIOLOGY REFLECTIONS
Teter-ing into Advertising Anesthetic Services
Generated by developing a photograph on postcard-backed paper, “real photo postcards” (RPPCs)
becameaconvenientway for hospitals, andperhapsdoctor-anesthetists, to advertise their services in the
early 1900s. Although dentists vacillated about whether advertising was professional, they generally
advertised more readily than their physician colleagues. However, poorly remunerated physician-anes-
thetists might certainly have felt economic pressures to advertise their services. Inscribed with “William-
sport Hospital Dr.,” this RPPC (above) features a dapper doctor-anesthetist (dentist or physician?) sporting a
moustache and a bowtie. The anesthesia machine was manufactured by the Teter Manufacturing
Company of Cleveland, Ohio. (Copyright © the American Society of Anesthesiologists, Inc. This image
also appears in the Anesthesiology Reflections online collection available at www.anesthesiology.org.)
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